Blue Longevity Clinic Secures €2M To Make Longevity Medicine More Accessible In Southeast Europe

The funding round was led by Bulgaria-based Eleven Ventures, with support from Sofia Angels Ventures and several family offices.

“The transition from reactive sick care to proactive health care is no longer a trend; it’s a global shift,” says Valeri Petrov, Partner at Eleven Ventures. “We’ve been closely tracking this category and believe the SEE region has the potential to become a key hub for medical and longevity tourism.”

“Blue Longevity is one of the first companies locally to combine medical credibility, product depth, and entrepreneurial experience into a scalable model.”

Blue Longevity Clinic will use the funding to expand across Southeast Europe, with new clinics set to open in Athens, Istanbul, and Sofia this September. These clinics will be supported by the company’s own digital tools and diagnostic protocols.

Read Also - Metly Secures €520K Pre-Seed Round To Accelerate pharma product launches with AI

The funds will go toward setting up the clinics, completing therapy protocols, growing the medical team, and advancing its app and AI diagnostics engine to scale and personalise services.

Milen Ivanov, Managing Partner at Sofia Angels Ventures, says, “Longevity is becoming the new frontier of healthcare – no longer a privilege reserved for eccentric biohackers, reclusive yogis, or billionaires. The science is already advancing at scale, and this will become a trillion-euro industry that helps millions live longer, healthier lives.”

“We believe in BL’s team and their ability to execute on their next healthcare venture, especially given the ripe timing for this mission.”

Interest in preventive health and longevity is growing, thanks to voices like Dr. Peter Attia, David Sinclair, and Peter Diamandis. Yet, Blue Longevity Clinic notes that advanced diagnostics and treatments have mostly been limited to wealthy individuals through exclusive clinics.

In Southeast Europe, longevity medicine is still in its early stages, often beyond the capabilities of traditional hospitals. Blue Longevity Clinic aims to change that by bringing these services to the region’s emerging upper-middle class—where out-of-pocket healthcare spending is among the highest in Europe.

Clients receive physician-led health plans supported by therapies like Hyperbaric Oxygen Therapy, Cryotherapy and Red Light Therapy. AI tools help analyze biomarkers and generate progress reports, enabling continuous, personalized care aimed at delaying age-related decline and supporting long-term wellness.

Founder and CEO, Ilian Grigorov says “We’re building a new kind of health centre – one that people don’t just visit once a year, but one that becomes part of their lifestyle. Longevity is not a single test or therapy – it’s a journey.”

“Our goal is to be the first truly integrated and accessible preventive health platform in the region and one of the global leaders in providing longevity medicine services.”

Alongside founder Ilian Grigorov, the Blue Longevity Clinic team includes Blagoy Palev, a former banker and co-founder of Blocks Health, and Dr. George Vissarakis, a specialist in rehabilitation medicine and former director at Greece’s Filoktitis Centre.

The round’s lead investor, Eleven Ventures, is an early-stage VC fund focused on South, Central, and Eastern Europe. Since 2012, it has backed over 180 startups in sectors like fintech, healthcare, AI, and climate tech.

Sofia Angels Ventures (SAV), a co-investing VC fund supported by the European Investment Fund, also joined the round. SAV invests in European startups with global potential, especially in healthtech, AI, and the future of work.

About Blue Longevity Clinic

Founded by healthcare entrepreneur Ilian Grigorov, the clinic offers a fully integrated model combining in-person diagnostics, therapy programs, and a digital app that promotes behavior change through microhabits. The focus is on extending healthspan by detecting early signs of aging in metabolism, brain function, the gut microbiome, and genetics.